Company intelligence / Profile preview

VelaVigo

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

VelaVigo has built a robust pipeline of novel multi-specific biologics. Its lead asset, a first-in-class bispecific antibody (VBS-102), was outlicensed ex-China to Ollin Biosciences in a deal worth up to $440 million. Another major deal with Avenzo Therapeutics for a Nectin4/TROP2 bispecific ADC could reach $750 million if all milestones are met. The company raised $50M in pre-A funding in February 2025 and plans to initiate US clinical trials for its lead program within the year[3][5][6].

Therapeutic areas: Oncology
Modalities: Multi-specific antibodiesBispecific antibodiesAntibody-drug conjugates (ADCs)
Industry: Biotech

Drug pipeline

3 assets

VBC101

2 more assets in the full pipeline.

Request access →

Partnerships

Ollin Biosciences (out-license of VBS-102)[3][5]Avenzo Therapeutics (out-license of Nectin4xTROP2 bispecific ADC)[3][5]

Beyond the preview

Go deeper on VelaVigo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VelaVigo.

Explore the full profile